|Bid||2.5700 x 800|
|Ask||2.6300 x 1100|
|Day's Range||2.6000 - 2.7300|
|52 Week Range||2.2100 - 4.7500|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Subscribe to Yahoo Finance Plus to view Fair Value for ELYM
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in